CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03769467
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:08.157048+00:00
Published At: 2024-11-14T00:00:00+00:00
Record Updated At: 2024-11-14
Results Posted At: 2024-11-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Nasopharyngeal Carcinoma", "Nasopharyngeal Neoplasms", "Epstein-Barr Virus Infections", "Epstein-Barr Viraemia", "Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-11-14"
protocolSection.identificationModule.nctId: "NCT03769467"
protocolSection.identificationModule.officialTitle: "An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-11-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.